Vineet Laboratories Share Price Today | Stock Price & Vineet Laboratories Share Screener
As of October 5, 2026, the live Vineet Laboratories share price (NSE: VINEETLAB) is ₹37.57 on NSE and ₹37.84 on BSE, up 4.62% from the previous close, with shares trading between ₹35.49 and ₹37.70 in today's trading session, and a 52-week range of ₹29.01–₹47.87. Check VINEETLAB price range for the annual price range and momentum. Use the Vineet Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Vineet Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹59 and net income of ₹1, with EBITDA of ₹8, an operating margin of 14.0% and a profit margin of 1.7%.
Vineet Laboratories Share Price Chart
Track the current stock price of Vineet Laboratories with an interactive chart. Analyse VINEETLAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Vineet Laboratories stock quote in one place.
The quote of ₹37.57 sits between the 52-week low of ₹29.01 and the 52-week high of ₹47.87, and the latest session moved 4.62% from the previous close.
Vineet Laboratories Company Profile - Fundamental Screener
Screen Vineet Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VINEETLAB shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE505Y01010.
Company Details
Classification
Identifiers and Leadership
Vineet Laboratories Balance Sheet Screener
Screen VINEETLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹125, up from ₹95 in 2025.
Latest statistics put total assets at ₹125 and shareholder funds at ₹46, with a leverage ratio of 1.71.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
Assets |
||||||||
| Total Assets | 125 | 95 | 117 | 116 | 133 | 109 | 0 | 0 |
| Current Assets | 99 | 67 | 88 | 88 | 103 | 86 | 0 | 0 |
| Fixed Assets | 24 | 26 | 27 | 27 | 21 | 20 | 0 | 0 |
Liabilities |
||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 12 | 6 | 6 | 8 | 5 | 8 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||
| Total Equity | 46 | 15 | 35 | 34 | 33 | 27 | 0 | 0 |
| Share Capital | 19 | 9 | 9 | 9 | 9 | 9 | 0 | 0 |
| Reserves & Surplus | 26 | 5 | 26 | 25 | 24 | 17 | 0 | 0 |
Vineet Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Vineet Laboratories income statement and profit fundamentals. Analyze VINEETLAB quarterly results. Vineet Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-March, revenue was ₹59 and net profit was ₹1, equal to earnings per unit of ₹1.00, at an operating margin of 14%.
In that period expenses were ₹51, interest cost ₹5 and tax ₹0. The next period listed, 2025-March, shows revenue of ₹77 and net profit of ₹-20.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||
| Revenue | 59 | 77 | 151 | 212 | 192 | 244 | 0 | 0 |
| Expenses | 51 | 91 | 143 | 205 | 178 | 235 | 0 | 0 |
Operating Costs and Margins | ||||||||
| EBITDA | 8 | -14 | 8 | 8 | 13 | 9 | 0 | 0 |
| Operating Profit % | 14.00% | -22.00% | 5.00% | 4.00% | 7.00% | 3.00% | 0.00% | 0.00% |
| Depreciation | 2 | 3 | 3 | 2 | 2 | 2 | 0 | 0 |
| Interest | 5 | 4 | 5 | 3 | 2 | 3 | 0 | 0 |
Profit and Earnings | ||||||||
| Profit Before Tax | 1 | -21 | 0 | 2 | 9 | 4 | 0 | 0 |
| Tax | 0 | -1 | -1 | 1 | 3 | 2 | 0 | 0 |
| Net Profit | 1 | -20 | 1 | 1 | 7 | 2 | 0 | 0 |
| EPS | 1.00 | -21.90 | 1.11 | 1.36 | 7.16 | 2.18 | -0.27 | 0.00 |
Vineet Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen VINEETLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹12.
Over the same period, investing activities used ₹3 and financing activities used ₹8.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||
| Operating Activities | 12 | -7 | -10 | 8 | 28 | 0 |
| Investing Activities | -3 | -2 | -7 | -4 | -8 | 0 |
Financing and Net Cash | ||||||
| Financing Activities | -8 | 8 | 0 | 12 | 19 | 0 |
| Net Cash Flow | 0 | 0 | -16 | 16 | 38 | 0 |
Vineet Laboratories Shareholding Pattern Screener
See Vineet Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Vineet Laboratories promoter holding and ownership changes for VINEETLAB on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Feb, promoters held 5.98%, foreign institutions 0.00%, domestic institutions 0.00% and the public 89.17%, spread across 10,042 shareholders.
The shareholder count was 10,042 in 2026-Feb, compared with 9,929 in 2026-Mar.
| Item | 2026-Feb | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 5.98% | 5.98% | 5.98% | 35.85% | 29.26% | 15.89% | 12.46% | 37.50% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.36% | 0.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 89.17% | 88.74% | 88.17% | 58.67% | 66.95% | 78.16% | 82.41% | 59.07% |
| Other Holding | 4.84% | 4.92% | 5.34% | 5.49% | 3.79% | 5.94% | 5.12% | 3.42% |
| Shareholder Count | 10,042 | 9,929 | 9,901 | 10,025 | 9,988 | 9,682 | 10,003 | 9,638 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Vineet Laboratories. Vineet Laboratories dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹1.00 | 2.86% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Vineet Laboratories Stock Index Membership - Nifty & Sensex
See which indices include Vineet Laboratories stock. Check VINEETLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Vineet Laboratories Market Events Screener - Corporate Actions
Get Vineet Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Vineet Laboratories stock events that may affect VINEETLAB share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 25, 2026, with a record date of August 25, 2026.
It is followed by Quarterly Result Announcement dated July 15, 2026 and Quarterly Result Announcement dated February 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-25 | 2026-08-25 | Quarterly Result Announcement | NA | 8.61% |
| 2026-07-15 | 2026-07-15 | Quarterly Result Announcement | NA | 7.51% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | -1.49% |
| 2026-02-07 | 2026-02-07 | Extraordinary General Meeting | NA | -14.72% |
| 2025-12-23 | 2025-12-23 | Rights | 13:12 | 0.84% |
| 2025-11-08 | 2025-11-08 | Quarterly Result Announcement | NA | -2.38% |
| 2025-10-23 | 2025-10-23 | Quarterly Result Announcement | NA | 2.39% |
| 2025-09-25 | 2025-09-25 | Annual General Meeting | NA | 26.25% |
| 2025-07-22 | 2025-07-22 | Quarterly Result Announcement | NA | -19.58% |
| 2025-05-12 | 2025-05-12 | Quarterly Result Announcement | NA | -13.11% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -6.92% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 2.63% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | -4.14% |
| 2023-09-28 | 2023-09-28 | Annual General Meeting | NA | -0.32% |
| 2022-09-19 | 2022-09-20 | Dividend | ₹ 1.00 /share | 14.41% |
Vineet Laboratories Competitors Screener - Peer Stocks Comparison
Screen VINEETLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 447,476 | 36.44 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 250,363 | 86.51 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 186,152 | 85.91 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 120,798 | 26.32 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 111,426 | 33.44 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 106,838 | 99.70 | 6,868 | 22.01% | 890 | 58.00 |
| Mankind Pharma | 105,107 | 48.73 | 14,636 | 14.85% | 1,938 | 64.24 |
| Dr Reddys Laboratories | 104,492 | 32.05 | 35,059 | 3.90% | 4,158 | 69.59 |
| Aurobindo Pharma | 97,682 | 26.36 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,829 | 16.99 | 29,039 | 26.75% | 5,356 | 34.02 |
Vineet Laboratories Company Announcements - News & Reports Screener
Screen VINEETLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 26, 2026.
The next most recent announcements are dated August 29, 2026 and August 25, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-26 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Grant Of Extension Of Time By The Registrar Of Companies For Holding The 10St Annual General Meeting Of The Company | - |
| 2026-08-29 | Results-Delay in Financial Results | - |
| 2026-08-25 | Results-Delay in Financial Results | - |
| 2026-08-25 | Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday August 25 2026 As Required Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-20 | Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-07-30 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-21 | Announcement under Regulation 30 (LODR)-Resignation of Managing Director | - |
| 2026-07-21 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-07-16 | Intimation Of Diferment Of Board Meeting | - |
| 2026-07-11 | Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-05-30 | Outcome Of Board Meeting Held On May 30 2026 - Deferment Of Consideration Of Audited Standalone Financial Results | - |
| 2026-05-29 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-05-26 | Board Meeting Intimation for To Consider And Approve The Audited Standalone Financial Results Of The Company For The Fourth Quarter And The Financial Year Ended March 31St 2026. | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-04-21 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-30 | Closure of Trading Window | - |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-14 | Unaudited Standalone Financial Results Along With The Limited Review Report For The Period Ended On December 31 2025 | - |
| 2026-02-14 | Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday February 14 2026 As Required Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹37.57, within a 52-week range of ₹29.01 to ₹47.87. The P/E ratio is 60.17 and the P/B ratio is 1.47, with earnings per unit of ₹1.00. Market capitalisation stands at ₹70.53 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 8 balance sheet periods, 8 income statement periods, 6 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.